List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Since this article was published last December, Net Pricing Drug Channel developments have accelerated. Manufacturers reduced the list prices

By Drug Channels · Apr 8, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.